Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Broadcom Inc (AVGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Broadcom Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $279.77 (market cap $39.89B), while Broadcom Inc trades at $391.66 (market cap $1.90T). The key difference: Broadcom Inc is far larger — about 47.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Broadcom Inc pays a 0.65% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | AVGO | |
|---|---|---|
Market Cap | $39.89B | $1.90T |
Sector | Health | Technology |
52-Week High | $491.22 | $481.57 |
52-Week Low | $278.09 | $274.38 |
Enterprise Value | $38.15B | $1.95T |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Broadcom (AVGO) trades at $399.97, down 0.28% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $2.44 versus $2.40, continuing a pattern of earnings outperformance. Recent news highlights a significant $30 billion Apple chip supply deal extending through 2031, providing substantial revenue visibility for its custom AI silicon operations.
Broadcom presents a compelling growth story driven by AI semiconductor demand and strategic partnerships, with analyst consensus strongly bullish (86% buy ratings) and a $510.43 price target suggesting 28% upside. Key risks include high valuation multiples (P/E 66.55) and dependence on major customers like Apple, though strong cash flow generation ($27.54B operating cash flow in 2025) supports dividend payments and debt reduction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →
